Advertisement

Clinical and biochemical characteristics of early depression in Parkinson’s disease

  • W. Kuhn
  • G. Fuchs
  • G. Laux
  • R. Rupprecht
  • H. Przuntek
Part of the Key Topics in Brain Research book series (KEYTOPICS)

Summary

Depression is more prominent in untreated patients in the early phase of the disease than in treated patients who have suffered from Parkinson’s disease more than six years. In depressive Parkinson patients low levels of urinary 3-methoxy-4-hydroxyphenylglycol (MHPG) and an abnormal Dexamethasone Suppression Test were found. Although a reactive component could not be excluded, both pharmacological and biochemical data support the hypothesis that alterations in norepinephrine metabolism could be the cause for depression in Parkinson’s disease.

Keywords

Parkinson Patient Motor Disability Dexamethasone Suppression Test Endogenous Depression Early Depression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE (1980) Antidepressive treatment in Parkinson’s disease. Acta Neurol Scand 62: 210–219PubMedCrossRefGoogle Scholar
  2. Cagnasso M, Biondi PA (1974) Gaschromatographic estimation of urinary vanilmandelicacid and 3-methoxy-4-hydroxyphenylethyleneglycol after their purification on Sephadex LH 20. Ital J Biochem 5: 345–355Google Scholar
  3. Celesia GG, Wanamaker WM (1972) Psychiatric disturbances in Parkinson’s disease. Dis New System 33: 577–583Google Scholar
  4. Demel I, Schubert H, Unterthiner D (1980) Initialsymptome bei depressiven Erkrankungen. Neurol Psychiat 6: 263–266Google Scholar
  5. Gotham AM, Brown RG, Marsden CD (1986) Depression in Parkinson’s disease: a quantitative and qualitative analysis. Neurol Neurosurg Psychiatr 49: 381–389CrossRefGoogle Scholar
  6. Kawamura T, Kinoshita M, Iwasaki Y, Nemoto H (1987) Low-dose dexamethasone suppression test in Japanese patients with Parkinson’s disease. J Neurol 234: 264–265PubMedCrossRefGoogle Scholar
  7. Kopin IJ, Jimerson DC, Markey SP, Ebert MH, Polinski RJ (1984) Disposition and metabolism of MHPG in humans: Application to studies in depression. Pharmacopsychiatry 17: 3–8PubMedCrossRefGoogle Scholar
  8. Mayeux R, Stern Y, Cote L, Williams JBW (1984) Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology 34: 642–646PubMedGoogle Scholar
  9. Mindham RHS, Marsden CD, Parkes JD (1976) Psychiatric symptoms during L-Dopa therapy for Parkinson’s disease and their relationship to physical disability. Psychol Med 6: 23–33PubMedCrossRefGoogle Scholar
  10. Riederer P, Birkmayer W (1980) A new concept: brain area specific imbalance of neurotransmitters in depression syndrome—human brain studies. In: Usdin E, Sourkes TL, Youdim MBH (eds) Enzymes and neurotransmitters in mental disease. Wiley, New York, p 261Google Scholar
  11. Robins AH (1976) Depression in patients with parkinsonism. Br J Psychiatr 128: 141–145CrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1989

Authors and Affiliations

  • W. Kuhn
    • 4
  • G. Fuchs
    • 1
  • G. Laux
    • 2
  • R. Rupprecht
    • 2
  • H. Przuntek
    • 3
  1. 1.Departments of NeurologyUniversity of WürzburgGermany
  2. 2.Departments of PsychiatryUniversity of WürzburgGermany
  3. 3.Department of NeurologySt. Josef University-HospitalBochumFederal Republic of Germany
  4. 4.Department of PsychiatryUniversity of WürzburgWürzburgFederal Republic of Germany

Personalised recommendations